阿德福韦酯治疗拉米夫定耐药慢性乙型肝炎的临床效果和安全性

Clinical Effect and Safety of Adefovir Dipivoxil in the Treatment of Lamivudine-resistant Chronic Hepatitis B

目的分析阿德福韦酯治疗拉米夫定耐药慢性乙型肝炎的临床效果和安全性。方法该研究选取了2018年1月—2019年12月该院接收的100例拉米夫定耐药慢性乙型肝炎患者作为研究对象,将100例患者随机进行分组,50例作为对照组研究对象,50例作为观察组研究对象,对照组给予拉米夫定口服治疗,观察组在对照组基础上联合阿德福韦酯进行治疗,比较两组患者HBV-DNA转阴率、ALT复常率、病毒学指标变化情况、安全性分析。结果观察组治疗12个月后HBV-DNA转阴率为96.00%、对照组为74.00%,差异有统计学意义(χ^(2)=9.490,P=0.002);观察组治疗12个月后ALT复常率为100.00%、对照组为74.00%,差异有统计学意义(χ^(2)=14.943,P=0.001);观察组治疗后HBsAb为56.00%、对照组为76.00%,差异有统计学意义(χ^(2)=4.456,P=0.035);观察组治疗后HBeAg为96.00%、对照组为50.00%,差异有统计学意义(χ^(2)=26.839,P=0.001);观察组安全性为96.00%、对照组为82.00%,差异有统计学意义(χ^(2)=5.005,P=0.025)。结论阿德福韦酯治疗拉米夫定耐药慢性乙型肝炎有显著临床治疗效果,有临床应用价值,可推广。

Objective To analyze the clinical effect and safety of adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B.Methods In this study,100 patients with lamivudine-resistant chronic hepatitis B received in the hospital from January 2018 to December 2019 were selected as the research object,100 patients were randomly divided into groups,and 50 patients were used as the control group.50 cases were taken as the study objects of the observation group.The control group was given lamivudine oral treatment,and the observation group was treated with adefovir dipivoxil on the basis of the control group.The two groups were compared with HBV-DNA negative rate,ALT return to normal rate,changes in virological indicators,and safety analysis.Results After 12 months of treatment in the observation group,the HBV-DNA conversion rate was 96.00%,and the control group was 74.00%,the difference was statistically significant(χ^(2)=9.490,P=0.002);the observation group’s ALT recovery rate after 12 months of treatment was 100.00%,and the control group was 74.00%,the difference was statistically significant(χ^(2)=14.943,P=0.001);HBsAb after treatment in the observation group was 56.00%,and the control group was 76.00%,the difference was statistically significant(χ^(2)=4.456,P=0.035);the observation group After treatment,HBeAg was 96.00%,the control group was 50.00%,the difference was statistically significant(χ^(2)=26.839,P=0.001);the safety of the observation group was 96.00%,the control group was 82.00%,the difference was statistically significant(χ^(2)=5.005,P=0.025).Conclusion Adefovir dipivoxil has a significant clinical therapeutic effect in the treatment of lamivudine-resistant chronic hepatitis B.It has clinical application value and can be promoted.